Celgene Drops GED-0301 as Crohn’s Therapy but Will Continue Testing It for Ulcerative Colitis

Celgene Drops GED-0301 as Crohn’s Therapy but Will Continue Testing It for Ulcerative Colitis
Celgene Corporation is giving up on GED-0301 as a Crohn's disease therapy, but will continue to evaluate its ability to treat ulcerative colitis. It ended its Phase 3 REVOLVE clinical trial (NCT02596893) and its SUSTAIN extension trial (NCT02641392) of GED-0301 as a potential Crohn's treatment after an independent trial monitoring board recommended the discontinuations. The board had reviewed the therapy's benefits and risks, and the implication of its recommendation was that GED-0301 failed to generate enough benefits. The review board recommendation prompted Celgene to cancel its plans for the Phase 3 DEFINE trial (
Subscribe or to access all post and page content.